Skip to main content

Table 1. DMD characteristics included and excluded in the patient decision aid

From: Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development

Characteristic BWS RIS Mean (SD) New categorization of characteristic
Included in the patient decision aid   
Effect on relapse rate 7.76 (2.58) Effect on relapses
Effect on the severity of relapse 7.39 (2.32)
Safety 6.04 (2.95) Safety (risk of severely disabling and life-threatening adverse events)
Uncertainty about long-term consequences 4.58 (2.76)
Required monitoring 0.55 (1.18) Required monitoring
Severity of side effects 7.63 (2.11) Risk of common side effects
Type of side effects 5.00 (2.71)
Duration of side effects 3.74 (1.97)
Influence on life style 5.31 (2.92) Ease of use
Mode of administration 1.58 (2.69)
Frequency of administration 0.68 (1.38)
Duration of administration 0.20 (0.24)
Effect on disability progression 9.64 (1.16) Effect on disability progression (based on EDSS)
Effect on QoL 9.21 (1.45) Effect on QoL (based on PRO)
Effect on development of plaques in the brain 7.31 (2.52) Effect on development of plaques in the brain
Effect on current MS symptoms 7.32 (1.97) Effect on fatigue (based on PRO)
   Effect on cognition (based on PRO)
Omitted from the patient decision aid   
Effect on life expectancy 4.81 (3.13)  
Pace of effect 3.18 (2.19)  
Interaction with other medication 1.72 (1.86)  
Insurance coverage 2.71 (2.87)  
Mode of action of DMD 0.99 (1.25)  
Total DMD costs 0.86 (1.27)  
Further development of DMD 0.87 (0.94)  
Composition of DMD 0.18 (0.36)  
Use of DMD among other MS patients 0.34 (0.56)  
Ease of travelling 0.29 (0.87)  
Contact person at pharmaceutical company 0.10 (0.28)  
  1. BWS, best-worst scaling; DMD, disease-modifying drugs; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PRO, patient-reported outcome; QoL, quality of life; RIS, relative importance score; SD, standard deviation